Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab

Core Insights - Summit Therapeutics Inc. (NASDAQ:SMMT) is recognized as one of the best growth stocks under $25, particularly following the announcement of the expansion of its Phase 3 clinical development program for Ivonescimab [1][2] Company Overview - Summit Therapeutics Inc. is a biotechnology company focused on developing therapies primarily for cancer treatment [3] Clinical Development - The Phase 3 clinical program, named HARMONi-GI3, will evaluate Ivonescimab in combination with chemotherapy for patients with unresectable metastatic colorectal cancer [2] - The trial will compare the efficacy of Ivonescimab plus chemotherapy against bevacizumab plus chemotherapy as a first-line treatment for colorectal cancer [2] - The management aims to enroll approximately 600 patients globally, with trial sites in the United States expected to commence soon [2]